The costs of diabetes in 2020 and 2030 − A model analysis comparing innovative glucose lowering treatments in second line following European and American guidelines compared to current standard of care

Adam Fridhammar (), Emelie Andersson () and Katarina Steen Carlsson ()

No 2016:9, IHE Report / IHE Rapport from IHE - The Swedish Institute for Health Economics

Abstract: A previous report estimated the long-term complications and societal costs of type 2 diabetes in 2020 and 2030 in Sweden (IHE Report 2015:1). That analysis showed that a more intensive treatment strategy, with more frequent health care contacts and a lower threshold for treatment change, reduces the risk of premature death and lead to fewer microvascular and macrovascular complications. By year 2030, the more intensive treatment strategy was cost-neutral.

This report (IHE Report 2016:9) updates the previous one by evaluating the effects from including DPP-4 inhibitors, GLP-1 agonists and SGLT-2 inhibitors in second-line treatment. This treatment strategy is estimated to reduces the risk of premature death and decrease microvascular and macrovascular complications compared to a strategy similar to current standard of care in Sweden. At the current price level, the total societal cost was estimated to increase due to the use DPP-4 inhibitors, GLP-1 agonists and SGLT-2 inhibitors. When accounting for expected price reduction due to future patent expiries, the total societal cost was instead estimated to decrease by year 2030.

Keywords: diabetes (search for similar items in EconPapers)
Date: 2016
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://ihe.se/wp-content/uploads/2016/10/IHE-Report_2016_9_.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hhs:ihewps:2016_009

Access Statistics for this paper

More papers in IHE Report / IHE Rapport from IHE - The Swedish Institute for Health Economics
Bibliographic data for series maintained by Annette Persson Dietmann ().